Effect of trimetazidine and benazepril combined therapy on RAAS and quality of life in patients with coronary heart disease and heart failure
Objective To investigate the effects of trimetazidine combined with benazepril on renin-angiotensin-aldo-sterone system(RAAS)and quality of life in patients with coronary heart disease combined with heart failure.Methods Totally 136 patients with coronary heart disease and heart failure admitted to the Yellow River Central Hospi-tal of the Yellow River Water Conservancy Commission from September 2020 to September 2022 were randomly divided into 68 patients in the single drug group and 68 patients in the combined group.The RAAS related indicators[angioten-sin Ⅱ(Ang Ⅱ),aldosterone(ALD)and plasma renin activity(PRA)],oxidative stress level[malondialdehyde(MDA),superoxide dismutase(SOD)],matrix metalloproteinase[matrix metalloproteinase-9(MMP-9),matrix met-alloproteinase-2(MMP-2)],blood lipid level[low/high-density lipoprotein cholesterol(L/HDL-C),triglyceride(TG),total cholesterol(TC)],cardiac function related indicators[left ventricular ejection fraction(LVEF),6-mi-nute walking distance(6WMT)],quality of life[evaluated using the SF-36 health survey scale],and clinical effica-cy were compared in two groups before and after treatment.Results Compared with before treatment,the levels of Ang Ⅱ,PRA,ALD,SOD,MMP-9,MMP-2,LDL-C,TC and TG in the two groups were significantly decreased after treatment,while the levels of MDA,HDL-C,LVEF,6WMT and SF-36 scores were significantly increased(P＜0.05).The change range of combination group was higher than that of monotherapy group(P＜0.05).The total effective rate in combination group was 82.35％,which was significantly higher than 63.24％in monotherapy group.Conclusion The combined treatment of trimetazidine and benazepril has significant effect on patients with coronary heart disease combined with heart failure,which can effectively regulate RAAS,alleviate patients'oxidative stress re-sponse,inhibit myocardial remodeling,improve dyslipidemia and cardiac function.
Coronary heart diseaseHeart failureTrimetazidineBenazeprilRenin-angiotensin-aldosterone systemQuality of life
NETL
NSTL
万方数据
